Skip to content
← All treatment topics

TREATMENT READING

Myelodysplastic/Myeloproliferative Neoplasms

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

32 sections
  1. Treatment of Chronic Myelomonocytic Leukemia
  2. Disease Overview
  3. Treatment Overview
  4. Allogeneic stem cell transplant (SCT)
  5. Hypomethylating agents
  6. Hydroxyurea
  7. Hypomethylating agent versus hydroxyurea
  8. Other regimens
  9. Treatment of Juvenile Myelomonocytic Leukemia
  10. Treatment of Atypical Chronic Myeloid Leukemia
  11. Disease Overview
  12. Treatment Overview
  13. Treatment of MDS/MPN, Unclassifiable
  14. Disease Overview
  15. Treatment Overview
  16. Certain factors affect prognosis (chance of recovery) and treatment options.
  17. Treatment Option Overview
  18. Key Points
  19. There are different types of treatment for patients with myelodysplastic/myeloproliferative neoplasms.
  20. The following types of treatment are used:
  21. Watchful waiting
  22. Chemotherapy
  23. Other drug therapy
  24. Stem cell transplant
  25. Supportive care
  26. Targeted therapy
  27. New types of treatment are being tested in clinical trials.
  28. Treatment for myelodysplastic/myeloproliferative neoplasms may cause side effects.
  29. Follow-up care may be needed.
  30. Treatment of Chronic Myelomonocytic Leukemia
  31. Treatment of Atypical Chronic Myeloid Leukemia
  32. Treatment of Myelodysplastic/ Myeloproliferative Neoplasm, Unclassifiable

Health professional

Treatment of Chronic Myelomonocytic Leukemia

Source: Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Health professional · Treatment of Chronic Myelomonocytic Leukemia

Disease Overview

Source: Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

The World Health Organization (WHO) classifies chronic myelomonocytic leukemia (CMML) as a myelodysplastic/myeloproliferative neoplasm (MDS/MPN).[1] The WHO recognizes a dysplastic subtype and a proliferative subtype, with prognostic groups differentiated by the circulating white blood cell (WBC) count or the percentage of blasts in the bone marrow (higher percentage with worse prognosis).[2]

Sources: 1 · 2

CMML is a clonal disorder of a bone marrow stem cell. Monocytosis is a major defining feature. CMML exhibits heterogenous clinical, hematological, and morphological features, varying from predominantly myelodysplastic to predominantly myeloproliferative. Evolution to acute myeloid leukemia (AML) portends a particularly poor prognosis.[3]

Sources: 3

CMML is characterized pathologically by:[4,5]

Sources: 4 · 5

Persistent monocytosis is greater than 1 × 109/L in the peripheral blood.

No Philadelphia chromosome or BCR::ABL1 gene fusion.

No PDGFRA and PDGFRB rearrangement.

Fewer than 20% blasts in the blood or bone marrow (including monoblasts/promonocytes).

Dysplasia involving one or more myeloid lineages or, if myelodysplasia is absent or minimal, either an acquired clonal cytogenetic bone marrow abnormality or at least 3 months of persistent peripheral blood monocytosis, if all other causes are ruled out.

Clinical features of CMML include:[4,5]

Sources: 4 · 5

Fever, fatigue, night sweats, and weight loss. For more information, see Fatigue, Hot Flashes and Night Sweats, and Nutrition in Cancer Care.

Sources: Fatigue · Hot Flashes and Night Sweats · Nutrition in Cancer Care

Infection.

Bleeding caused by thrombocytopenia.

Hepatomegaly (in some patients).

Splenomegaly (in some patients).

In patients with a WBC count that is within reference range or slightly decreased, clinical features may be identical to MDS.

In patients with elevated WBC count, features are more like chronic myeloproliferative disorders, including more frequent splenomegaly and hepatomegaly.

The median age at diagnosis of CMML is 65 to 75 years with a male predominance of 1.5 to 3.1.[4,5] Because CMML is grouped with chronic myeloid leukemia in some epidemiologic surveys and with MDS in others, no reliable incidence data are available for CMML.[6] Although the specific etiology of CMML is unknown, exposure to occupational and environmental carcinogens, ionizing radiation, and cytotoxic agents has been associated in some cases.[6]

Sources: 4 · 5 · 6 · 6

Morphologically, the disease is characterized by a persistent peripheral blood monocytosis (always >1 × 109/L) that may exceed 80 × 109/L with monocytes typically accounting for more than 10% of the WBCs.[4,5] Monocytes, though typically mature with an unremarkable morphology, can exhibit abnormal granulation, unusual nuclear lobation, or finely dispersed nuclear chromatin.[7] Fewer than 20% blasts are seen in the blood or bone marrow. Neutrophilia occurs in nearly 50% of patients with neutrophil precursors (e.g., promyelocytes and myelocytes) accounting for more than 10% of the WBCs.[8] Mild normocytic anemia is common. Moderate thrombocytopenia is often present. Bone marrow findings include:[4,5,9,10]

Sources: 4 · 5 · 7 · 8 · 4 · 5 · 9 · 10

Hypercellularity (75% of cases).

Blast count less than 20%.

Granulocytic proliferation (with dysgranulopoiesis).

Monocytic proliferation, dyserythropoiesis (e.g., megaloblastic changes, abnormal nuclear contours, ringed sideroblasts, etc.).

Micromegakaryocytes and/or megakaryocytes with abnormally lobated nuclei (as many as 80% of the cases).

Fibrosis (30% of the cases).

Hepatosplenomegaly may be present.[4,5] Autoimmune phenomena, including pyoderma gangrenosum, vasculitis, and idiopathic thrombocytopenia have been observed in CMML.[11] Care should be taken to identify cases of CMML with eosinophilia, a subtype of CMML, because of its association with severe tissue damage secondary to eosinophil degranulation. In CMML with eosinophilia, all criteria for CMML are present, and the eosinophil count in the peripheral blood is more than 1.5 × 109/L.[6]

Sources: 4 · 5 · 11 · 6

Recurrent somatic pathogenic variants have been identified in most patients with CMML, resulting in altered signaling molecules (especially NRAS, KRAS, JAK2, and SETBP1), epigenetic regulators (especially TET2 and ASXL1), splicing factors (especially SRSF2), and transcription factors (especially RUNX1).[12-15] A CMML-specific prognostic scoring system can distinguish four risk groups based on the following factors:[16]

Sources: 12 · 15 · 16

Red blood cell transfusion dependency.

WBC count at least 13 × 109/L.

Bone marrow blasts at least 5%.

Genetic risk group based on cytogenetics (trisomy 8, ≥3 abnormalities on karyotype, or chromosome 7 abnormalities are high risk), and pathogenic variants in ASXL1, NRAS, RUNX1, or SETBP1.

The best prognostic group has a median survival of more than 10 years with no leukemic evolution in the first decade of follow-up. The worst prognostic group has a median survival of 20 months with a 50% evolution to AML by 2 years.[16]

Sources: 16

Prognostic factors associated with shorter survival include:[17,18]

Sources: 17 · 18

Low hemoglobin level.

Low platelet count; high WBC, monocyte, and lymphocyte counts.

Presence of circulating immature myeloid cells.

High percentage of marrow blasts.

Low percentage of marrow erythroid cells.

Abnormal molecular genetic data.

High levels of serum lactate dehydrogenase and beta-2-microglobulin.

Progression to acute leukemia occurs in approximately 15% to 20% of cases.[17,18]

Sources: 17 · 18

CPSS-Mol is a CMML-specific prognostic scoring system that incorporates molecular genetic data, especially pathogenic variants in RUNX1, NRAS, SETBP1, and ASXL1. This system distinguishes low-risk disease with median survivals longer than 10 years from high-risk disease with median survivals of 2 to 4 years.[16]

Sources: 16

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Treatment of Chronic Myelomonocytic Leukemia

Treatment Overview

Source: Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

CMML is a diagnosis typically made after age 70 years. The clinical course of CMML ranges from indolent or smoldering disease to an aggressive disease progression culminating in severe cytopenias or evolution to acute leukemia. Assessment of the risk factors and the pace of disease over time may help to distinguish patients who require therapy from those who would be best managed with a watchful waiting approach. Asymptomatic patients at low risk of progression may be best served by forgoing therapy.[19,20]

Sources: 19 · 20

Health professional · Treatment of Chronic Myelomonocytic Leukemia / Treatment Overview

Allogeneic stem cell transplant (SCT)

Source: Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Patients with high-risk disease who are young enough and fit enough may undergo allogeneic SCT. This represents the only potential cure for CMML. Hypomethylating agents like azacitidine and decitabine are usually given prior to allogeneic SCT for cytoreduction or to ameliorate cytopenias.[21,22] Retrospective reports that included small numbers of patients with CMML (range, 12–80) who underwent allogeneic SCT reported recurrence rates of 20% to 40% and 5-year overall survival (OS) rates of approximately 20% to 30%.[23-28][Level of evidence C3]

Sources: 21 · 22 · 23 · 28 · Level of evidence C3

A retrospective review of 1,114 patients with CMML diagnosed between 2000 and 2014 included 384 patients who underwent allogeneic SCT.[29] With a median follow-up of 51 to 78 months (in two data sets), allogeneic SCT in patients with low-risk CMML was detrimental, with a 5-year OS rates of 20% for patients who underwent allogeneic SCT and 42% for patients who did not undergo allogeneic SCT (P < .001).[29][Level of evidence C1] For patients with high-risk CMML, there was no statistically significant difference in 5-year OS rates among patients treated with or without allogeneic SCT (27% vs. 15%, respectively; P = .13).

Sources: 29 · 29 · Level of evidence C1

Health professional · Treatment of Chronic Myelomonocytic Leukemia / Treatment Overview

Hypomethylating agents

Source: Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Two randomized prospective clinical trials compared the hypomethylating agent, azacitidine, with best supportive care in patients with myelodysplastic syndromes (MDS). The trials involved large numbers of patients with MDS but also included small numbers of patients (fewer than 25) with CMML.[30,31] The overall response rates exceeded 60% for all patients who received azacitidine, but the data did not allow an assessment specifically for patients with CMML.[30,31][Level of evidence C3] Several phase II trials reported response rates of 30% to 60% for patients with CMML who received hypomethylating agents.[32-36] Azacitidine and decitabine may reverse cytopenias, cytoreduce elevated WBC counts, reduce splenic size, and improve clinical symptoms (like decreased appetite or itching).

Sources: 30 · 31 · 30 · 31 · Level of evidence C3 · 32 · 36

Health professional · Treatment of Chronic Myelomonocytic Leukemia / Treatment Overview

Hydroxyurea

Source: Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Hydroxyurea has been given for other diseases with chronic myeloproliferation, such as thrombocythemia and myelofibrosis. These applications suggest the use of hydroxyurea for CMML with leukocytosis, thrombocytosis, or splenomegaly.[37] In a randomized prospective clinical trial of 105 patients with CMML, hydroxyurea (up to 4 g/day) was compared with etoposide.[38] With a median follow-up of 11 months, the median OS was 20 months in patients who received hydroxyurea and 9 months in patients who received etoposide (P < .0001).[38][Level of evidence A1]

Sources: 37 · 38 · 38 · Level of evidence A1

Health professional · Treatment of Chronic Myelomonocytic Leukemia / Treatment Overview

Hypomethylating agent versus hydroxyurea

Source: Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

In a prospective randomized trial, 170 patients with newly diagnosed advanced CMML received intravenous decitabine or hydroxyurea (1–4 g/day). With a median follow-up of 17.5 months, there was no statistically significant difference in event-free survival (12.1 months for patients who received decitabine and 10.3 months for patients who received hydroxyurea; hazard ratio, 0.83; 95% confidence interval [CI], 0.59–1.16; P = .27). There was also no statistically significant difference in median OS (16.3 months for patients who received decitabine and 21.9 months for patients who received hydroxyurea; P = .67).[39][Level of evidence A1] Although decitabine reduced CMML progression or transformation to AML by 38% compared with hydroxyurea, this was offset by a 55% increase in deaths that were not caused by progression (the deaths were usually related to infection). There are no data to suggest that systematic antibiotic prophylaxis would have helped the patients who received decitabine.

Sources: 39 · Level of evidence A1

Health professional · Treatment of Chronic Myelomonocytic Leukemia / Treatment Overview

Other regimens

Source: Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

In a phase II trial, 13 hypomethylating agent–naive patients with high-risk CMML were treated with azacitidine or decitabine plus venetoclax. With a median follow-up of 14.1 months, the overall response rate was 85% (11 of 13 patients), including two with complete response and a median duration of response of 17.9 months.[40,41][Level of evidence C3] Six of these patients underwent subsequent allogeneic SCT.

Sources: 40 · 41 · Level of evidence C3

A retrospective study included 21 patients with high-risk CMML who received cladribine plus low-dose cytarabine alternating with azacitidine or decitabine. The patients had an objective response rate of 33% (50% in patients with hypomethylating agent–naive CMML and 23% in patients with hypomethylating agent–failure CMML).[41][Level of evidence C3]

Sources: 41 · Level of evidence C3

A phase I/II study of 23 patients with mostly high-risk MDS and greater than 5% marrow blast cells involved 10 patients with CMML. All patients received azacitidine plus venetoclax. With a median follow-up of 13.2 months, the overall response rate was 87% (95% CI, 66%–97%).[42][Level of evidence C3]

Sources: 42 · Level of evidence C3

Health professional

Treatment of Juvenile Myelomonocytic Leukemia

Source: Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

For more information, see Juvenile Myelomonocytic Leukemia Treatment.

Sources: Juvenile Myelomonocytic Leukemia Treatment

Health professional

Treatment of Atypical Chronic Myeloid Leukemia

Source: Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Health professional · Treatment of Atypical Chronic Myeloid Leukemia

Disease Overview

Source: Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Atypical chronic myeloid leukemia (aCML) is a leukemic disorder that exhibits both myelodysplastic and myeloproliferative features at the time of diagnosis.

Atypical CML is characterized pathologically by:[1]

Sources: 1

Peripheral blood leukocytosis with increased numbers of mature and immature neutrophils.

Prominent dysgranulopoiesis.

No Philadelphia chromosome or BCR::ABL1 gene fusion.

Neutrophil precursors (e.g., promyelocytes, myelocytes, and metamyelocytes) accounting for more than 10% of white blood cells.

Minimal absolute basophilia with basophils accounting for less than 2% of white blood cells.

Absolute monocytosis with monocytes typically account for less than 10% of white blood cells.

Hypercellular bone marrow with granulocytic proliferation and granulocytic dysplasia.

Fewer than 20% blasts in the blood or bone marrow.

Thrombocytopenia.

Clinical features of aCML include:[1-4]

Sources: 1 · 4

Anemia. For more information on anemia, see Fatigue.

Sources: Fatigue

Thrombocytopenia.

Splenomegaly (in 75% of cases).

Although cytogenetic abnormalities are found in as many as 80% of the patients with aCML, none is specific.[1-3,5] No Philadelphia chromosome or BCR::ABL1 gene fusion is present.

Sources: 1 · 3 · 5

The exact incidence of aCML is unknown. The median age at the time of diagnosis of this rare leukemic disorder is in the seventh or eighth decade of life.[1-3]

Sources: 1 · 3

Morphologically, aCML is characterized by myelodysplasia associated with bone marrow and peripheral blood patterns similar to chronic myeloid leukemia, but cytogenetically it lacks a Philadelphia chromosome or BCR::ABL1 gene fusion.[1] The white blood cell count in the peripheral blood is variable. Median values range from 35 × 109/L to 96 × 109/L, and some patients may have white blood cell counts greater than 300 × 109/L.[1-3,5] Blasts in the peripheral blood typically account for less than 5% of the white blood cells. Immature neutrophils usually total 10% to 20% or more.[1] The percentage of monocytes is rarely more than 10%. Minimal basophilia may be present.[1-3,5] Nuclear abnormalities, such as acquired Pelger-Huët anomaly, may be seen in the neutrophils. Moderate anemia (often showing changes indicative of dyserythropoiesis) and thrombocytopenia are common.[1-4] Bone marrow findings include: [1-3,5]

Sources: 1 · 1 · 3 · 5 · 1 · 1 · 3 · 5 · 1 · 4 · 1 · 3 · 5

Granulocytic hypercellularity.

Blast count less than 20%.

Dysgranulopoiesis

Megakaryocytic dysplasia.

Erythroid precursors accounting for more than 30% of marrow cells with dyserythropoiesis present (in some cases).

The median survival times for aCML are reported to be less than 20 months, and thrombocytopenia and marked anemia are poor prognostic factors.[1,2] Atypical CML evolves to acute leukemia in approximately 25% to 40% of patients.[1,3] In the remaining patients, fatal complications include resistant leukocytosis, anemia, thrombocytopenia, hepatosplenomegaly, cerebral bleeding associated with thrombocytopenia, and infection.[3,4]

Sources: 1 · 2 · 1 · 3 · 3 · 4

Health professional · Treatment of Atypical Chronic Myeloid Leukemia

Treatment Overview

Source: Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

The optimal treatment of aCML is uncertain because of the rare incidence of this chronic leukemic disorder. Treatment with hydroxyurea may lead to short-lived partial remissions of 2 to 4 months in duration.[4] Atypical CML appears to respond poorly to treatment with interferon alfa.[4]

Sources: 4 · 4

Health professional

Treatment of MDS/MPN, Unclassifiable

Source: Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Health professional · Treatment of MDS/MPN, Unclassifiable

Disease Overview

Source: Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-UC) (also known as mixed myeloproliferative/myelodysplastic syndrome, unclassifiable and overlap syndrome, unclassifiable) shows features of both myeloproliferative disease and myelodysplastic disease but does not meet the criteria for any of the other MDS/MPN entities.[1]

Sources: 1

Diagnostic criteria for MDS/MPN-UC can be either:[1]

Sources: 1

The combination of four sets of criteria (a–d):

The combination of four sets of criteria (a–d):

Clinical, laboratory, and morphological features of myelodysplastic syndrome (MDS) (e.g., refractory anemia, refractory anemia with ringed sideroblasts, refractory cytopenia with multilineage dysplasia, and refractory anemia with excess of blasts) with fewer than 20% blasts in the blood and bone marrow. For more information on anemia, see Fatigue.

Sources: Fatigue

Prominent myeloproliferative features, e.g. platelet count greater than 600 × 109/L associated with megakaryocytic proliferation, or white blood cell count greater than 13.0 × 109/L with or without splenomegaly.

No history of an underlying chronic myeloproliferative disorder (CMPD), MDS, or recent cytotoxic or growth factor therapy that could cause the myelodysplastic or myeloproliferative features.

No Philadelphia chromosome or BCR::ABL1 gene fusion, del(5q), t(3;3)(q21;q26), or inv(3)(q21q26).

Mixed myeloproliferative and myelodysplastic features that cannot be assigned to any other category of MDS, CMPD, or MDS/MPN.

Clinical characteristics of MDS/MPN-UC include:

Features of both MDS and CMPD.

Hepatomegaly.

Splenomegaly.

The incidence and etiology of MDS/MPN-UC are unknown.

Laboratory features typically include anemia and dimorphic erythrocytes on the peripheral blood smear.[1] Thrombocytosis (platelet count >600 × 109/L) or leukocytosis (white blood cell count >13 × 109/L) are present. Neutrophils may exhibit dysplastic features, and giant or hypogranular platelets may be present. Blasts make up less than 20% of the white blood cells and of the nucleated cells of the bone marrow. The bone marrow is hypercellular and may exhibit proliferation in any or all of the myeloid lineages. Dysplastic features are present in at least one cell line.[1]

Sources: 1 · 1

No cytogenetic or molecular findings are available that are specific for MDS/MPN-UC. In one small series, six of nine patients (those with ringed sideroblasts associated with marked thrombocytosis [RARS-T]) had JAK2 V617F variants, which caused constitutive activation of the JAK2 tyrosine kinase. This JAK2 pathogenic variant is also commonly observed in patients with polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis.[2] Because of its rare occurrence, the prognosis and predictive factors are unknown.[1]

Sources: 2 · 1

Health professional · Treatment of MDS/MPN, Unclassifiable

Treatment Overview

Source: Myelodysplastic/Myeloproliferative Neoplasms Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 14, 2025. Captured 2026-09-09.

Adult patients with MDS/MPN associated with platelet-derived growth factor receptor gene rearrangements are candidates for imatinib mesylate at standard dosages.[3] Because of its rare occurrence, the literature only minimally addresses other treatment options for MDS/MPN-UC. Supportive care involves treating cytopenias and infection as necessary.

Sources: 3

For patients · Chronic Myelomonocytic Leukemia

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

The prognosis and treatment options for CMML depend on:

Sources: prognosis

the number of white blood cells or platelets in the blood or bone marrow

whether the patient is anemic

Sources: anemic

the amount of blasts in the blood or bone marrow

the amount of hemoglobin in red blood cells

Sources: hemoglobin

whether there are certain changes in the chromosomes

Sources: chromosomes

For patients

Treatment Option Overview

Source: Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

There are different types of treatment for patients with myelodysplastic/myeloproliferative neoplasms.

The following types of treatment are used:

The following types of treatment are used:

Watchful waiting

Chemotherapy

Other drug therapy

Stem cell transplant

Supportive care

Targeted therapy

New types of treatment are being tested in clinical trials.

Treatment for myelodysplastic/myeloproliferative neoplasms may cause side effects.

Follow-up care may be needed.

For patients · Treatment Option Overview

There are different types of treatment for patients with myelodysplastic/myeloproliferative neoplasms.

Source: Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Different types of treatments are available for patients with myelodysplastic/myeloproliferative neoplasms. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.

Sources: standard · clinical trials · research study

For patients · Treatment Option Overview

The following types of treatment are used:

Source: Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment are used:

Watchful waiting

Source: Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Watchful waiting is closely monitoring a patient's condition without giving any treatment until signs or symptoms appear or change. It is sometimes used to treat chronic myelomonocytic leukemia in patients with no or mild symptoms.

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy

Source: Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy). Combination chemotherapy is treatment using more than one anticancer drug.

Sources: Chemotherapy · injected · systemic chemotherapy

For more information, see Drugs Approved for Myeloproliferative Neoplasms or Myelodysplastic Syndromes.

Sources: Drugs Approved for Myeloproliferative Neoplasms or Myelodysplastic Syndromes

For patients · Treatment Option Overview / The following types of treatment are used:

Other drug therapy

Source: Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

13-cis retinoic acid is a vitamin-like drug that slows the cancer's ability to make more cancer cells and changes the way these cells look and act.

Sources: 13-cis retinoic acid · vitamin

For patients · Treatment Option Overview / The following types of treatment are used:

Stem cell transplant

Source: Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Chemotherapy is given to kill abnormal cells or cancer cells. Healthy cells, including blood-forming cells, are also destroyed by the cancer treatment. Stem cell transplant is a treatment to replace the blood-forming cells. Stem cells (immature blood cells) are removed from the blood or bone marrow of the patient or a donor and are frozen and stored. After the patient completes chemotherapy, the stored stem cells are thawed and given back to the patient through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.

Sources: abnormal · blood · Stem cell transplant · Stem cells · bone marrow · donor · infusion

For patients · Treatment Option Overview / The following types of treatment are used:

Supportive care

Source: Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Supportive care is given to lessen the problems caused by the disease or its treatment. Supportive care may include transfusion therapy or drug therapy, such as antibiotics to fight infection.

Sources: Supportive care · transfusion · antibiotics · infection

For patients · Treatment Option Overview / The following types of treatment are used:

Targeted therapy

Source: Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific cancer cells.

Sources: Targeted therapy

Tyrosine kinase inhibitor (TKI) therapy: TKI therapy blocks signals that tumors need to grow. TKIs block the enzyme tyrosine kinase that causes stem cells to become more blood cells (blasts) than the body needs. Imatinib mesylate (Gleevec) is used to treat myelodysplastic/myeloproliferative neoplasm, unclassifiable.

Sources: Tyrosine kinase inhibitor · tumors · enzyme · blasts · Imatinib mesylate

For more information, see Drugs Approved for Myeloproliferative Neoplasms or Myelodysplastic Syndromes.

Sources: Drugs Approved for Myeloproliferative Neoplasms or Myelodysplastic Syndromes

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

For some people, joining a clinical trial may be an option. There are different types of clinical trials for people with cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.

You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trial search · ClinicalTrials.gov

Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.

Sources: Clinical Trials Information for Patients and Caregivers

For patients · Treatment Option Overview

Treatment for myelodysplastic/myeloproliferative neoplasms may cause side effects.

Source: Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Follow-up care may be needed.

Source: Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

For patients

Treatment of Chronic Myelomonocytic Leukemia

Source: Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of chronic myelomonocytic leukemia (CMML) may include:

Sources: chronic myelomonocytic leukemia

watchful waiting

Sources: watchful waiting

chemotherapy with one or more agents

Sources: chemotherapy

stem cell transplant

Sources: stem cell transplant

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Atypical Chronic Myeloid Leukemia

Source: Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of atypical chronic myeloid leukemia (CML) may include chemotherapy.

Sources: chronic myeloid leukemia · chemotherapy

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Myelodysplastic/ Myeloproliferative Neoplasm, Unclassifiable

Source: Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 6, 2025. Captured 2026-09-09.

For information about the treatments listed below, see the Treatment Option Overview section.

Sources: Treatment Option Overview

Because myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-UC) is a rare disease, little is known about its treatment. Treatment may include:

Sources: myelodysplastic · myeloproliferative · neoplasm

supportive care treatments to manage problems caused by the disease such as infection, bleeding, and anemia

Sources: supportive care · infection · anemia

targeted therapy (imatinib mesylate)

Sources: targeted therapy · imatinib mesylate

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

Studies

INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

NCT01164163 · COMPLETED · phase1

Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific

ClinicalTrials.gov record

Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer

NCT00014495 · COMPLETED · phase1, phase2

Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms

ClinicalTrials.gov record

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

NCT00027560 · COMPLETED · phase2

Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms

ClinicalTrials.gov record

Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes

NCT00045305 · COMPLETED · phase2

Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms

ClinicalTrials.gov record

Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes

NCT00072475 · COMPLETED · phase2

Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms

ClinicalTrials.gov record

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

NCT00245037 · COMPLETED · phase1, phase2

Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms,...

ClinicalTrials.gov record

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

NCT00255684 · TERMINATED · na

Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms

ClinicalTrials.gov record

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

NCT00281879 · TERMINATED · phase2

Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms,...

ClinicalTrials.gov record

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

NCT00293384 · COMPLETED · na

Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes,...

ClinicalTrials.gov record

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

NCT00513474 · COMPLETED · phase1

Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes,...

ClinicalTrials.gov record

Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer

NCT00516503 · COMPLETED · phase3

Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes,...

ClinicalTrials.gov record

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

NCT00589563 · COMPLETED · phase2

Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes,...

ClinicalTrials.gov record

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

NCT00691015 · COMPLETED · phase2

Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms

ClinicalTrials.gov record

American Ginseng in Treating Patients With Fatigue Caused by Cancer

NCT00719563 · COMPLETED · phase3

Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes,...

ClinicalTrials.gov record

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

NCT00755040 · COMPLETED · phase3

Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes,...

ClinicalTrials.gov record

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

NCT01116232 · TERMINATED · phase2

Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic...

ClinicalTrials.gov record

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

NCT01118013 · TERMINATED · phase2

Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms

ClinicalTrials.gov record

Disease and treatment settings

Myelodysplastic/Myeloproliferative Neoplasms

Disease and treatment setting

Myelodysplastic/Myeloproliferative Neoplasms